Literature DB >> 23784939

On model specification and selection of the Cox proportional hazards model.

Chen-Yen Lin1, Susan Halabi.   

Abstract

Prognosis plays a pivotal role in patient management and trial design. A useful prognostic model should correctly identify important risk factors and estimate their effects. In this article, we discuss several challenges in selecting prognostic factors and estimating their effects using the Cox proportional hazards model. Although a flexible semiparametric form, the Cox's model is not entirely exempt from model misspecification. To minimize possible misspecification, instead of imposing traditional linear assumption, flexible modeling techniques have been proposed to accommodate the nonlinear effect. We first review several existing nonparametric estimation and selection procedures and then present a numerical study to compare the performance between parametric and nonparametric procedures. We demonstrate the impact of model misspecification on variable selection and model prediction using a simulation study and an example from a phase III trial in prostate cancer.
Copyright © 2013 John Wiley & Sons, Ltd.

Entities:  

Keywords:  COSSO; Cox model; LASSO; model selection; smoothing splines

Mesh:

Substances:

Year:  2013        PMID: 23784939      PMCID: PMC3795916          DOI: 10.1002/sim.5876

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  17 in total

1.  Sample size determination for comparing several survival curves with unequal allocations.

Authors:  Susan Halabi; Bahadur Singh
Journal:  Stat Med       Date:  2004-06-15       Impact factor: 2.373

2.  Survival prediction of diffuse large-B-cell lymphoma based on both clinical and gene expression information.

Authors:  Lexin Li
Journal:  Bioinformatics       Date:  2005-12-08       Impact factor: 6.937

3.  A Selective Overview of Variable Selection in High Dimensional Feature Space.

Authors:  Jianqing Fan; Jinchi Lv
Journal:  Stat Sin       Date:  2010-01       Impact factor: 1.261

4.  Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

Authors:  William Kevin Kelly; Susan Halabi; Michael Carducci; Daniel George; John F Mahoney; Walter M Stadler; Michael Morris; Philip Kantoff; J Paul Monk; Ellen Kaplan; Nicholas J Vogelzang; Eric J Small
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

5.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

6.  Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

Authors:  Susan Halabi; Eric J Small; Philip W Kantoff; Michael W Kattan; Ellen B Kaplan; Nancy A Dawson; Ellis G Levine; Brent A Blumenstein; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

Review 7.  The importance of identifying and validating prognostic factors in oncology.

Authors:  Susan Halabi; Kouros Owzar
Journal:  Semin Oncol       Date:  2010-04       Impact factor: 4.929

8.  PENALIZED VARIABLE SELECTION PROCEDURE FOR COX MODELS WITH SEMIPARAMETRIC RELATIVE RISK.

Authors:  Pang Du; Shuangge Ma; Hua Liang
Journal:  Ann Stat       Date:  2010-08-01       Impact factor: 4.028

9.  Dimension reduction methods for microarrays with application to censored survival data.

Authors:  Lexin Li; Hongzhe Li
Journal:  Bioinformatics       Date:  2004-07-15       Impact factor: 6.937

10.  Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study.

Authors:  A Zeleniuch-Jacquotte; R E Shore; K L Koenig; A Akhmedkhanov; Y Afanasyeva; I Kato; M Y Kim; S Rinaldi; R Kaaks; P Toniolo
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  2 in total

Review 1.  Analysis of Survival Data: Challenges and Algorithm-Based Model Selection.

Authors:  Kaushik Sarkar; Ranadip Chowdhury; Aparajita Dasgupta
Journal:  J Clin Diagn Res       Date:  2017-06-01

2.  High Jagged1 expression is associated with poor outcome in primary glioblastoma.

Authors:  Xian-Xin Qiu; Chen-Hong Wang; Na You; Bi-Juan Chen; Xing-Fu Wang; Yu-Peng Chen; Zhi-Xiong Lin
Journal:  Med Oncol       Date:  2014-11-26       Impact factor: 3.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.